Targeted therapy is used after stem cell transplant to lower the risk of neuroblastoma coming back. Targeted therapy fights cancer by finding a specific substance (target), such as a protein, on cancer cells.
After stem cell transplant, patients get a type of targeted therapy called monoclonal antibodies. These are manmade versions of antibodies – immune system proteins that fight disease. The antibodies target a substance (GD2) on neuroblastoma cells. The antibody then triggers the immune system to kill the neuroblastoma cells.